Breast Cancer
Dr Chloe Grimmett presented findings from a pilot study on a web-based support tool for young breast cancer patients considering genetic testing for BRCA1/2.
The authors present their findings from a study aiming to determine the relationships of anxiety, social desirability, and demographics with group cohesion within a group intervention for African American breast cancer survivors.
The PARP inhibitor olaparib significantly improved progression-free survival (PFS) compared with standard chemotherapy in women with HER2-negative metastatic breast cancer with a germline BRCA mutation. Disease progression was delayed by about 3 months with olaparib in the multinational, randomized, open-label phase 3 study known as OlympiAD, reported Mark E. Robson, MD, at the 2017 ASCO Annual Meeting.
Cancer costs are rising, but the implementation of evidence-based quality improvement strategies in early-stage breast cancer care can reduce costs and improve patient quality of life, according to Angie Meillier, RN, MS, from Abbott Northwestern Piper Breast Center in Minneapolis, MN.
Preliminary data show excellent and durable responses to atezolizumab in 10% of women with triple-negative breast cancer (TNBC), one of the most aggressive and difficult cancers to treat.
A case study demonstrating the importance of patient advocacy, respecting patients’ choices, and addressing barriers to care.
It is exciting to see that patients with advanced breast cancer are able to receive additional treatment options, because a primary concern of patients with stage IV breast cancer is a lack of awareness of laboratory and clinical research targeted for those battling advanced disease.
Based on the prevalence of invasive breast cancer, the amount of drug therapy required among a managed patient population is considerable, and significantly affects the top cancer trend therapies within the cancer budget for payers.
At the Markey Cancer Center in Lexington, KY, clinical pharmacists are integral members of the multidisciplinary care team, working in the clinic alongside surgical and medical oncologists, imaging specialists, radiation oncologists, pathologists, nurses, and other healthcare providers.
Mary Connolly, RN, BSN, Sarah F. Gallups, RN, PhD, MPH, Margaret Q. Rosenzweig, PhD, FNP-C, AOCN, FAAN, Jacqueline Simon, BA
The authors present findings on the secondary aim of the Adherence, Communication, Treatment, and Support (ACTS) randomized controlled intervention study – a one-time psychoeducational intervention encouraging adherence of African American women to prescribed chemotherapy.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512